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Introduction
NADPH oxidases (Noxs) are a family of reactive oxygen species–
generating (ROS-generating) enzymes with diverse pathophysiolog-
ical roles (1). The prototypic member of this family, Nox2, was first 
identified in neutrophils, where it is involved in the killing of phago-
cytized microorganisms. Nox2 is also expressed in other leukocytes 
and many nonhematopoietic cells, such as cardiomyocytes and 
endothelial cells, where it modulates redox-sensitive signaling path-
ways (2). Cellular Nox2 activation requires the assembly of mem-
brane-bound and cytoplasmic subunits into a multiprotein complex 
that transfers electrons from NADPH to molecular oxygen, a process 
that is stimulated by agonists such as angiotensin II (Ang II) (1).
Increased activation of the renin-angiotensin system is a major 
stimulus for pathological cardiovascular remodeling, contributing 
to hypertension, endothelial dysfunction, cardiac hypertrophy, and 
heart failure (3), and previous work has shown an important role for 
Nox2 in amplifying these processes (1, 2). Recent studies indicate 
that Nox2 has distinct roles in different cell types, and cell-specific 
contributions of endothelial cell and cardiomyocyte Nox2 to Ang II–
dependent cardiovascular remodeling have been reported (4–6). It 
has long been known that Nox2 is also expressed in T cells (7), but 
relatively little is known about the T cell–specific function of Nox2 
in Ang II–dependent hypertension and cardiovascular remodeling.
Previous work found that Ang II stimulates the synthesis of 
proinflammatory cytokines, chemokines, and adhesion molecules 
in the heart and vessels, inducing the recruitment and activation 
of T and B lymphocytes and dendritic and natural killer cells (8). 
In this setting, emerging evidence suggests that T cells participate 
in the genesis of hypertension (9). For instance, humanized mice 
in which the murine immune system was replaced by human leu-
kocytes showed greater hypertension after Ang II infusion along 
with increased infiltration of CD4+ cells in the aorta and kidney 
(10). Circulating CD4+ T cells from hypertensive patients pro-
duced more IFN-γ than cells from normotensive subjects, while 
in mice the inhibition of the B7/CD28 costimulatory axis with 
CTLA-4–Ig (cytotoxic T lymphocyte–associated protein 4, also 
called CD152) attenuated Ang II–induced hypertension and T 
cell accumulation in the aorta (10, 11). Specific T cell subsets also 
influence cardiac remodeling; for example, CD4+ but not CD8+ T 
cells are reported to promote the transition from pressure over-
load cardiac hypertrophy to failure (12). The importance of ROS 
in T cell functions in hypertension has been suggested by prior 
studies. It was found that mice lacking T and B cells (Rag1–/–) dis-
played blunted hypertensive responses to chronic Ang II infusion, 
and that the hypertensive response was restored after adoptive 
transfer of Nox2-competent T cells (13). It was also shown that 
Ang II–stimulated increase in TNF-α production by T cells was 
inhibited by scavenging ROS (14). However, the specific role of 
different Nox2-containing T cell subsets remains unknown.
The superoxide-generating enzyme Nox2 contributes to hypertension and cardiovascular remodeling triggered by activation 
of the renin-angiotensin system. Multiple Nox2-expressing cells are implicated in angiotensin II–induced (Ang II–induced) 
pathophysiology, but the importance of Nox2 in leukocyte subsets is poorly understood. Here, we investigated the role of 
Nox2 in T cells, particularly Tregs. Mice globally deficient in Nox2 displayed increased numbers of Tregs in the heart at baseline, 
whereas Ang II–induced effector T cell (Teff) infiltration was inhibited. To investigate the role of Treg Nox2, we generated 
a mouse line with CD4-targeted Nox2 deficiency (Nox2fl/flCD4Cre+). These animals showed inhibition of Ang II–induced 
hypertension and cardiac remodeling related to increased tissue-resident Tregs and reduction in infiltrating Teffs, including 
Th17 cells. The protection in Nox2fl/flCD4Cre+ mice was reversed by anti-CD25 antibody depletion of Tregs. Mechanistically, 
Nox2–/y Tregs showed higher in vitro suppression of Teff proliferation than WT Tregs, increased nuclear levels of FoxP3 and NF-
κB, and enhanced transcription of CD25, CD39, and CD73. Adoptive transfer of Tregs confirmed that Nox2-deficient cells had 
greater inhibitory effects on Ang II–induced heart remodeling than WT cells. These results identify a previously unrecognized 
role of Nox2 in modulating suppression of Tregs, which acts to enhance hypertension and cardiac remodeling.
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of Ang II on the heart, as these changes persist when blood 
pressure is normalized with the antihypertensive agent hydral-
azine (Supplemental Figure 1; supplemental material available 
online with this article; https://doi.org/10.1172/JCI97490DS1). 
We first studied the time course of cardiac T cell infiltration 
during chronic Ang II infusion. Immunostaining of cardiac 
sections revealed CD3+ cell infiltration as early as 3 days after 
Ang II treatment, with the cells being in perivascular clusters at 
days 3–7, whereas by day 14 leukocytes were mainly interstitial 
(Figure 1D). Flow cytometry analyses revealed a peak of CD45+ 
TCRβ+ cells after 3 days of Ang II treatment, comprising both 
CD4+ and CD8+ T cells (Figure 1, E–G).
Deficiency of Nox2 inhibits cardiac T cell infiltration in response 
to Ang II. In line with previous reports (15, 16), mice globally defi-
cient in Nox2 (Nox2–/y) showed attenuated hypertension, intersti-
Here, we investigated the role of Nox2 expressed in CD4+ 
T cells in the pathophysiology of Ang II–dependent hypertension 
and cardiovascular remodeling. Our results identify a hitherto 
unrecognized role of Nox2 in CD4+CD25+FoxP3+ Tregs whereby 
Nox2 limits their suppressive activity and allows infiltration/pro-
liferation of effector T cells (Teffs) to promote Ang II–dependent 
cardiovascular remodeling.
Results
Myocardial T cell infiltration occurs in a time-dependent manner 
during Ang II treatment. Chronic Ang II infusion (1.1 mg/kg/d 
for 14 days) induces significant hypertension, cardiac hyper-
trophy, and interstitial fibrosis in mice (Figure 1, A–C), as previ-
ously described (15, 16). A substantial component of the cardiac 
hypertrophy and fibrosis in this model is related to direct effects 
Figure 1. Myocardial T cell infiltration occurs during chronic Ang II infusion. WT mice were treated with Ang II infusion (1.1 mg/kg/d) or saline vehicle by 
osmotic minipumps. (A) Systolic blood pressure (BP) over 14 days of infusion. (B) Percentage interstitial cardiac fibrosis in myocardial sections (Picrosirius 
red staining). (C) Cardiomyocyte cross-sectional area (CSA) in myocardial sections, as an index of hypertrophy. (D) Myocardial sections stained with H&E 
(left) or immunohistochemistry using an anti-CD3 Ab (right). Scale bars: 50 μm. (E–G) Flow cytometry analyses of CD45+TCRβ+CD4+ and CD45+TCRβ+CD8+ 
T cells in heart digests. Representative plots are shown to the left, and mean data reported as cells per milligram tissue are shown to the right. *P < 0.05 
compared with the saline group by 2-way ANOVA (A, F, and G) or 1-way ANOVA followed by Tukey’s post-test (B and C); n = 5–8 per group.
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mates and were born in a normal Mendelian ratio (data not shown). 
Quantitative reverse transcription PCR and flow cytometry assays 
confirmed a significant reduction in Nox2 mRNA and protein lev-
els in CD4+ T cells from Nox2fl/flCD4Cre+ mice compared with WT 
littermates (Figure 3, B and C). Furthermore, stimulated CD4+ T 
cells from Nox2fl/flCD4Cre+ mice produced less ROS than CD4+ 
T cells from WT controls, and comparable ROS levels to those 
observed in Nox2fl/fl cells after Nox2 inhibition with the flavopro-
tein inhibitor diphenyleneiodonium (Figure 3D).
Under basal conditions, Nox2fl/flCD4Cre+ mice had a signifi-
cantly higher percentage and absolute number of Tregs in the heart 
than WT littermates (Figure 3, E and F), similar to the phenotype 
observed in the globally Nox2-deficient mice (Figure 2, G–I). The 
higher proportion of CD4+CD25+FoxP3+ Tregs in hearts of Nox2fl/fl 
CD4Cre+ mice was confirmed by augmented levels of CD25 mRNA 
(Figure 3G), and was accompanied by increased levels of CCR4, 
c-Met, and CXCR3 mRNAs (Figure 3, H–J), which may indicate an 
enhanced tissue tropism of Nox2-deficient as compared with WT 
Tregs (17). There was no difference in number of circulating CD4+ 
tial fibrosis, and cardiomyocyte hypertrophy after Ang II infusion, 
as compared with WT controls (Figure 2, A–C). Nox2–/y mice had 
a substantially lower cardiac infiltration of CD4+ and CD8+ T cells 
after chronic Ang II infusion (Figure 2, D–F) and a higher propor-
tion of CD4+CD25+FoxP3+ cells (Tregs) than WT littermates (Fig-
ure 2, G and H). Interestingly, analyses of cardiac-resident cells at 
baseline indicated a pronounced increase in both the proportion 
and the absolute numbers of Tregs in Nox2–/y as compared with 
WT mouse hearts (Figure 2, H and I).
These results suggest that Nox2 deficiency results in enhanced 
Treg numbers in the heart under basal conditions and after Ang II 
treatment, which may limit infiltration by Teffs and cardiovascu-
lar remodeling induced by Ang II.
In vivo role of Nox2 in CD4+ T cells and Tregs during Ang II infu-
sion. To identify the role of Nox2 in CD4+ T cells, we generated a 
novel strain of mice with a CD4-targeted Nox2 deficiency (Nox2fl/fl 
CD4Cre+) by crossing Nox2fl/fl mice with transgenic animals 
expressing CD4-targeted Cre recombinase (Figure 3A). Nox2fl/fl 
CD4Cre+ mice appeared morphologically similar to WT litter-
Figure 2. Effects of Ang II infusion on T cell infiltration in globally Nox2-deficient mice. Globally Nox2-deficient mice (Nox2–/y) and matched WT controls 
were treated with Ang II infusion (1.1 mg/kg/d). (A) Systolic BP was significantly lower in Nox2–/y compared with WT mice. (B) Interstitial cardiac fibrosis after 
Ang II infusion. Representative myocardial sections are shown to the right. Scale bars: 50 μm. (C) Cardiomyocyte cross-sectional area (CSA). (D–H) Flow cytom-
etry analyses of hearts 3 days after Ang II or saline (Sham) treatment. The numbers of CD45+TCRβ+CD4+ and CD45+TCRβ+CD8+ cells and representative plots 
are shown in D–F. The proportion of Tregs (CD45+TCRβ+CD4+CD25+FoxP3+ cells) is shown in G. (H and I) Flow cytometry analyses of the relative and absolute 
numbers of Tregs in hearts from WT and Nox2–/y mice under basal conditions and after Ang II infusion. *P < 0.05 compared with the respective WT group or for 
the comparison shown, by 2-way ANOVA (A), unpaired t test (B, C, and I), or 1-way ANOVA followed by Tukey’s post-test (E, F, and H); n = 5–8 per group.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
3 0 9 1jci.org   Volume 128   Number 7   July 2018
The Th17 subset of CD4+ T cells and IL-17 production have been 
implicated in the pathogenesis of Ang II–induced hypertension and 
remodeling, and may have reciprocal interactions with Tregs (18–
20). We found that Nox2fl/flCD4Cre+ mice had significantly lower 
levels of CD4+RORγT+ (Th17) cells in heart, aorta, and kidney after 
Ang II treatment (Figure 5, A–E). Additionally, the levels of IL-17 
were lower and those of IL-10 higher in Nox2fl/flCD4Cre+ mouse 
hearts compared with Nox2fl/fl controls after Ang II infusion (Figure 
5, F and G), consistent with a switch in Th17/Treg balance from pro- 
to antiinflammatory. To assess whether Nox2 deficiency in Teffs 
directly impacts on IL-17 production or whether Nox2-deficient 
Tregs indirectly inhibit IL-17–producing cells, we undertook cocul-
ture studies. CD4+CD25– cells (Teffs) from WT or Nox2–/y mice cul-
tured with antigen-presenting cells (APCs) in the presence of anti-
and CD8+ T cells between Nox2fl/flCD4Cre+ mice and Nox2fl/fl con-
trols, while basal T cell numbers in the spleen were significantly 
higher in Nox2fl/flCD4Cre+ mice (Supplemental Figure 2).
After chronic Ang II infusion, Nox2fl/flCD4Cre+ mice showed 
markedly lower numbers of infiltrating CD4+ and CD8+ T cells 
in the heart than Nox2fl/fl littermates, but a higher percentage of 
FoxP3+ cells as a subset of CD4+ T cells (Figure 4, A–D). Similar 
findings were also observed in the aorta and kidneys of Nox2fl/fl 
CD4Cre+ mice compared with Nox2fl/fl littermates (Supplemental 
Figure 3). The inhibition of CD4+ and CD8+ Teff infiltration was 
accompanied by a marked blunting of Ang II–induced hyperten-
sion, interstitial fibrosis, and cardiomyocyte hypertrophy (Fig-
ure 4, E–G). However, there was no difference in renal function 
between groups (Supplemental Figure 4, A–D).
Figure 3. Deficiency of Nox2 in CD4+ T cells increases numbers of cardiac-resident Tregs. (A) Schematic representation of the generation of Nox2fl/flCD4Cre+ 
mice. Ex, exon. (B) mRNA levels of Nox2 in purified CD4+ T cells or in total CD4– cells. (C) Nox2 expression by flow cytometry in CD4+ and CD4– T cells. (D) 
ROS estimated by flow cytometry of purified CD4+ T cells loaded with dihydroethidium after stimulation with anti-CD3 (4 μg/ml) and anti-CD28 (4 μg/ml). 
Representative figures are shown to the right and individual data to the left. MFI, mean fluorescence intensity. Some CD4+ T cells from Nox2fl/fl mice were 
incubated with the flavoprotein Nox inhibitor diphenyleneiodonium (DPI, 1 μM) before stimulation. (E and F) Flow cytometry analyses of Tregs (CD25+FoxP3+ 
cells in the CD45+TCRβ+CD4+ population) in hearts of Nox2fl/flCD4Cre+ and littermate Nox2fl/fl mice under basal conditions. Absolute numbers of Tregs are 
shown in F. (G–J) mRNA levels of CD25, CCR4, c-Met, and CXCR3 in hearts of Nox2fl/flCD4Cre+ and matched Nox2fl/fl mice. *P < 0.05 compared with control 
group by 1-way ANOVA followed by Tukey’s post-test (B–D) or unpaired t test (E–J); n = 3–7 per group.
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this observation may reflect targeting of Nox2 in CD8+ T cells in 
Nox2fl/flCD4Cre+ mice. Indeed, Nox2 expression was reduced in 
CD8+ and CD4+CD8+ T cells in the thymus of Nox2fl/flCD4Cre+ 
mice (Supplemental Figure 6C).
Taken together, these results indicate that Nox2 deficiency in 
Tregs limits Ang II–induced hypertension and cardiac remodeling.
Nox2-deficient Tregs are more suppressive than WT Tregs and have 
increased nuclear levels of FoxP3 and NF-κB activation. To investigate 
mechanisms underlying the protective effect of Nox2 deficiency in 
Tregs against Ang II–induced pathology, we first studied the impact 
of Nox2 deficiency on the function of CD4+CD25+ Tregs. In vitro 
suppression assays revealed that Nox2-deficient CD4+CD25+ Tregs 
were more efficient at inhibiting Teff proliferation induced by anti-
CD3ε plus APCs as compared with WT CD4+CD25+ Tregs (Figure 
6, A and B). Moreover, cocultures of Nox2-deficient CD4+CD25+ 
Tregs and WT CD4+ Teffs had higher levels of the antiinflammatory 
cytokine IL-10 in supernatants than cocultures of WT Tregs and WT 
Teffs (Figure 6C). There was no difference in proliferation between 
Nox2-deficient and WT Teffs (Supplemental Figure 7A). In cocul-
tures of WT Teffs/WT Tregs compared with WT Teffs/Nox2-de-
ficient Tregs, there was no difference in the levels of TNF-α and 
CD3ε antibody (Ab) produced similar levels of IL-17 (Figure 5H). 
However, WT Teffs cocultured with Nox2–/y Tregs produced signifi-
cantly lower levels of IL-17 than WT Teffs cocultured with WT Tregs 
(Figure 5H), suggesting that Nox2-deficient Tregs more efficiently 
block IL-17 production than WT Tregs. To define the specific role of 
Nox2-deficient Tregs in vivo, we depleted Tregs in Nox2fl/flCD4Cre+ 
mice by treatment with PC61 monoclonal anti-CD25 antibody 1 
day before commencing Ang II infusion (Supplemental Figure 5). 
The protection against Ang II–induced remodeling was abolished in 
anti-CD25–treated Nox2fl/flCD4Cre+ mice, and the animals devel-
oped a similar level of hypertension, hypertrophy, and fibrosis to 
that observed in WT mice undergoing Ang II infusion (Figure 5, 
I–K). Treatment with anti-CD25 Ab in control Nox2fl/fl mice did not 
significantly alter the level of Ang II–induced hypertension.
In addition to CD4+CD25+FoxP3+ Tregs (also known as 
conventional Tregs), CD8+FoxP3+ Tregs may also contribute 
to antiinflammatory effects. We found that the proportion of 
CD8+FoxP3+ Tregs was significantly higher in hearts and aorta 
of Ang II–treated Nox2fl/flCD4Cre+ mice than control Nox2fl/fl 
mice (Supplemental Figure 6, A and B). Since CD4 is expressed 
in double-positive T cells during development in the thymus, 
Figure 4. Nox2fl/flCD4Cre+ mice are resistant to development of hypertension and heart remodeling induced by Ang II treatment. Nox2fl/flCD4Cre+ and 
Nox2fl/fl littermate controls were treated with Ang II (1.1 mg/kg/d) or saline (Sham) infusion. (A–C) Number of CD45+TCRβ+CD4+ and CD45+TCRβ+CD8+ T cells 
in heart digests by flow cytometry after 3 days of Ang II treatment. (D) Relative numbers of Tregs in heart digests after 3 days of Ang II treatment. Rep-
resentative plots are shown to the left and mean data to the right. (E–G) Changes in systolic BP, interstitial cardiac fibrosis, and cardiomyocyte cross-sec-
tional area (CSA) 14 days after Ang II infusion. *P < 0.05 compared with Nox2fl/fl control group by 1-way ANOVA followed by Tukey’s post-test (B, C, F, and 
G), 2-way ANOVA (E), or unpaired t test (D); n = 5–11 per group.
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IFN-γ in supernatants (Supplemental Figure 7, B and C), showing 
that Nox2 deficiency in Tregs does not affect TNF-α and IFN-γ pro-
duction by Teffs although it reduces IL-17 production (Figure 5H).
Tregs suppress through different mechanisms, including the 
release of antiinflammatory cytokines (IL-10 and TGF-β) (21), 
inhibition of dendritic cell costimulation (CTLA-4–mediated 
antagonism of CD28 or CTLA-4 removing CD80/CD86 from 
APCs by transendocytosis) (22), synthesis of adenosine by coor-
dinated activity of the ectoenzymes CD39 and CD73 (23, 24), and 
direct induction of apoptosis of CD4+ or CD8+ Teffs (25). We found 
that Nox2-deficient Tregs expressed higher levels of mRNA for 
CTLA-4, CD39, and CD73 than WT Tregs (Figure 5, D–F). Addi-
Figure 5. Tregs in Nox2fl/flCD4Cre+ mice account for the inhibition of Ang II–induced hypertension and heart remodeling. Nox2fl/flCD4Cre+ and Nox2fl/fl 
littermate controls were treated with Ang II (1.1 mg/kg/d) or saline (Sham) infusion. (A–C) Relative and absolute numbers of CD45+CD4+RORγT+ (Th17) cells 
in heart digests by flow cytometry after 3 days of Ang II treatment. Representative plots are shown in A. (D and E) Absolute numbers of Th17 cells in aorta 
and kidney after 7 days of Ang II treatment. (F and G) Cardiac levels of IL-17 and IL-10 after 3 days of Ang II treatment. (H) Nox2–/y Tregs inhibit IL-17 produc-
tion by CD4+CD25– cells. WT or Nox2–/y CD4+CD25– cells were stimulated with antigen-presenting cells (APCs) and anti-CD3ε Ab in the presence or absence 
of WT or Nox2–/y Tregs for 3 days. (I) Systolic BP response to Ang II infusion in Nox2fl/flCD4Cre+ and Nox2fl/fl mice after treatment with anti-CD25 Ab (clone 
PC61, 500 μg/mouse, i.p.) to deplete Tregs. (J and K) Effect of anti-CD25 Ab treatment on interstitial cardiac fibrosis (J) and cardiomyocyte cross-sectional 
area (CSA) (K) in mice infused with Ang II. *P < 0.05 compared with Nox2fl/fl control group, †P < 0.05 for effect of anti-CD25 Ab in Nox2fl/flCD4Cre+ mice, by 
1-way ANOVA followed by Tukey’s post-test (B–H, J, and K) or 2-way ANOVA (I); n = 3–6 per group.
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tionally, Nox2-deficient Tregs expressed higher mRNA levels of 
the glucocorticoid-induced TNF-related receptor (GITR) (Figure 
5G), which has previously been shown to be related to prolifera-
tion and maintenance of the suppressive phenotype of Tregs (26). 
Increased protein levels of CTLA-4, CD39, CD73, and GITR in 
Nox2-deficient versus WT Tregs were further confirmed by flow 
cytometry (Supplemental Figure 8).
Substantial evidence indicates that the forkhead box P3 tran-
scription factor, FoxP3, plays a critical role in the development 
and function of CD4+CD25+ Tregs. Mutations of human FoxP3 
result in dysfunction or impaired development of Tregs and lead 
to immunodysregulation and diverse immune disorders (27, 28). 
Here, we first observed by imaging flow cytometry, confocal 
microscopy, and immunoblotting that Tregs deficient in Nox2 had 
increased nuclear levels of FoxP3 under basal conditions (Figure 
7A and Supplemental Figure 9). It was previously reported that 
FoxP3 associates with the NF-κB subunit p65 (also known as RelA) 
on the CD25 promoter, mediating the transcription of the CD25 
gene (also known as IL-2 receptor α chain or IL2RA) (29), and 
that an NF-κB–dependent transcriptional program promotes Treg 
identity and function (30). In addition, we recently demonstrated 
that the deficiency of Nox2 increases nuclear NF-κB activation in 
myeloid cells, secondary to changes in nuclear redox state (31). In 
line with these reports, we observed an enhanced colocalization 
of FoxP3 and p65 in stimulated Nox2-deficient versus WT Tregs 
(Figure 7B). Moreover, Nox2-deficient Tregs had higher nucle-
ar p65 levels after anti-CD3 plus anti-CD28 stimulation than 
WT Tregs, as evaluated by imaging flow cytometry and confocal 
microscopy (Figure 7, C and D). More direct assessment of NF-κB 
transcriptional activity was undertaken in Jurkat cells transfect-
ed with an NF-κB firefly reporter construct. In these cells, the 
inhibition of Nox2 by preincubation with gp91ds-tat (a selective 
peptide inhibitor of Nox2) resulted in a higher NF-κB activation 
after TNF-α stimulation than in cells preincubated with a scram-
bled peptide control (scrambled-tat) (Figure 7E). Finally, we found 
that Nox2-deficient Tregs expressed higher levels of CD25 mRNA 
(Figure 7F), consistent with the increased nuclear levels of FoxP3 
and p65. Also, there was enhanced phosphorylation of STAT5 
after stimulation with IL-2 (as a readout of functional CD25 activ-
ity) in Nox2-deficient Tregs compared with WT Tregs (Figure 7G).
Therefore, the increased suppressive activity of Nox2-deficient 
Tregs may be related to their increased nuclear levels of FoxP3 and 
enhanced NF-κB activation, which drives an increased expression 
of CD25 and other molecules mediating suppression of Teffs.
Adoptive transfer of Nox2-deficient Tregs inhibits Ang II–induced 
hypertension and heart remodeling. To validate the importance of 
Nox2 in Tregs in Ang II–induced cardiovascular remodeling, we 
performed adoptive transfer studies in which WT Tregs or Nox2–/y 
Figure 6. Tregs deficient in Nox2 are more suppressive than WT Tregs. (A and B) In vitro suppression assay using Tregs purified from spleen and lymph nodes 
of Nox2-deficient mice (Nox2–/y) and WT littermate controls. Cells were stimulated with APCs and anti-CD3ε Ab. Representative plots in B show proliferation 
of Teffs after 3 days of stimulation; numbers at the top are the ratio of Tregs to Teffs. Mean data are shown in A. The “IC50” is the ratio of Tregs/Teffs at which 
there was 50% suppression of Teff proliferation. (C) Levels of IL-10 in culture supernatants determined by cytometric bead array. The cell combinations that were 
cocultured are shown at the bottom. (D–G) Baseline levels of mRNA for CTLA-4, CD39, CD73, and GITR in Tregs purified from spleen and lymph nodes. *P < 0.05 
for highlighted comparisons, by 2-way ANOVA (A), 1-way ANOVA followed by Tukey’s post-test (C), or unpaired t test (D–G); n = 3–6 per group.
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Figure 7. Deficiency of Nox2 in Tregs increases nuclear levels of FoxP3 and NF-κB activation. (A) Representative ImageStream pictures (left) and mean 
similarity scores (right) for the colocalization of FoxP3 and DAPI in CD4+FoxP3+ cells (Tregs) under basal conditions. (B) Representative ImageStream 
pictures (left) and mean similarity scores (right) for the colocalization of FoxP3 and p65 in Tregs after anti-CD3 plus anti-CD28 stimulation. (C) Nuclear 
localization of p65 in Tregs after anti-CD3 plus anti-CD28 stimulation. CS, coefficient of similarity. Representative overlay histogram of similarity of p65/
DAPI in WT Tregs and Nox2–/y Tregs is shown to the right. (D) Colocalization of FoxP3 and p65 in the nucleus of Tregs by confocal microscopy. Scale bars: 7.5 
μm. (E) NF-κB transcriptional activity assessed by a luciferase promoter assay in Jurkat cells preincubated with a specific Nox2 peptide inhibitor, gp91ds-
tat (gp91ds, 30 μM), or a scrambled peptide control, scrambled-tat (sc-tat; 30 μM). Cells transfected with minimal promoter and thymidine kinase Renilla 
were used as controls. RLU, relative lumen units. (F) mRNA levels of CD25 in purified Tregs (CD4+CD25+). (G) Level of STAT5 phosphorylation (p-STAT5, 
Y694) assessed in purified Tregs (CD4+CD25+FoxP3+) by flow cytometry after 30 minutes of IL-2 (100 IU/ml) stimulation. Representative histogram shown 
to the right. MFI, mean fluorescence intensity. *P < 0.05 for highlighted comparisons by unpaired t test (A, B, and F), 2-way ANOVA (G), or 1-way ANOVA 
followed by Tukey’s post-test (C and E); n = 3 independent experiments except where shown otherwise.
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the higher suppressive activity of Nox2-deficient Tregs involves 
enhanced nuclear levels of FoxP3 and NF-κB activation, which 
may drive the expression of the IL-2 receptor CD25 and its down-
stream signaling via STAT5 phosphorylation (Figure 9). Despite 
Nox2 being expressed in multiple cell types that are potentially 
involved in Ang II–dependent pathology, we find that targeted 
inhibition of Nox2 in Tregs is sufficient to significantly ameliorate 
Ang II–induced hypertension and heart remodeling.
T cells express the Ang II receptor AT1, which is known 
to enhance T cell proliferation and modulate inflammato-
ry responses (32, 33). The importance of T cells in the patho-
genesis of hypertension has been recognized for many years, 
with most studies focusing on the role of T cells in aggravat-
ing hypertension, vascular remodeling, and renal dysfunction 
(10, 11, 13, 34). Moreover, the contribution of T cells to cardiac 
remodeling has been increasingly recognized during hyperten-
sion or pressure overload (12, 35). More recently, it has been 
found that Tregs (CD4+CD25+FoxP3+) can act to limit Ang 
II–induced inflammation and damage in the vasculature and 
heart, thereby reducing the extent of hypertension and cardi-
ac remodeling (36–40). However, the mechanisms that control 
these suppressive actions of Tregs in hypertension and cardiac 
remodeling were unclear. In the present study, we observe that 
Tregs were injected into WT mice immediately before initiation of 
Ang II infusion. Animals treated with either WT or Nox2–/y Tregs 
had lower numbers of CD4+ and CD8+ T cells in the heart as com-
pared with saline-treated controls (Figure 8, A and B). Mice that 
received Nox2–/y Tregs had a higher percentage of Tregs in the 
heart after Ang II treatment than mice injected with WT Tregs 
(Figure 8C). Adoptive transfer of Tregs, either WT or Nox2–/y, 
inhibited Ang II–induced hypertension, cardiac fibrosis, and car-
diomyocyte hypertrophy (Figure 8, D–G). Notably, the adoptive 
transfer of Nox2-deficient Tregs induced a greater inhibition of 
Ang II–induced hypertension and heart fibrosis than was observed 
with the adoptive transfer of WT Tregs (Figure 8, D and E). There-
fore, Tregs deficient in Nox2 are more protective than WT Tregs in 
the setting of hypertension and cardiac remodeling.
Discussion
The major novel finding of this study is that the expression of Nox2 
in CD4+CD25+FoxP3+ Tregs plays a vital role in their function to 
orchestrate Ang II–induced hypertension and cardiac remodel-
ing. We show that Nox2 in Tregs limits their suppressive activity 
and therefore allows an increase in the infiltration/proliferation 
of Teffs, including Th17 cells, which enhances Ang II–induced 
hypertension, cardiac fibrosis, and hypertrophy. Mechanistically, 
Figure 8. Effect of adoptive transfer of Nox2-deficient or WT Tregs on the response to Ang II infusion. WT mice were treated with Ang II infusion (1.1 
mg/kg/d, 14 days) by osmotic minipump. Immediately before minipump implantation, mice received 1 × 106 WT or Nox2–/y Tregs or saline control by i.v. 
injection. (A–C) Absolute numbers of CD45+TCR+CD4+ and CD45+TCR+CD8+ T cells and relative numbers of Tregs (CD25+FoxP3+) in the heart after 14 days of 
Ang II infusion. (D) Effect of adoptive transfer of Tregs on systolic BP. (E) Interstitial cardiac fibrosis in myocardial sections. Representative photomicro-
graphs are shown to the right (scale bars: 50 μm) and mean data to the left. (F) Echocardiographic interventricular septal thickness (IVS) as a marker of 
left ventricular hypertrophy. (G) Cardiomyocyte cross-sectional area (CSA) in myocardial sections. *P < 0.05 for highlighted comparisons by 1-way ANOVA 
followed by Tukey’s post-test (A–C and E–G) or 2-way ANOVA (D); n = 5–8 per group.
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lymphocytes, synergizes with p65 on a regulatory region of the 
CD25 promoter to mediate the transcriptional activation of the 
CD25 gene (29). We find increased CD25 expression in Nox2-defi-
cient Tregs, and, in keeping with this, these cells have higher levels 
of phosphorylated STAT5 compared with WT Tregs after IL-2 stim-
ulation. The crucial role of IL2R/STAT5 signaling in Treg-suppres-
sive function has recently been highlighted by the demonstration 
that ablation of STAT5 signaling compromised Treg suppression in 
vitro and in vivo (41). Moreover, Tregs with enhanced STAT5 acti-
vation express higher levels of proteins involved in cell adhesion, 
which results in higher interaction with dendritic cells and block-
ade of costimulatory molecule synthesis. It is also well established 
when Nox2 is deficient in Tregs, they are more suppressive in 
vitro, accumulate in the heart at baseline, and are protective 
against Ang II–induced hypertension and heart remodeling.
We investigated the mechanisms that may underlie the great-
er suppressive effects of Nox2-deficient compared with WT Tregs 
(defined as CD4+CD25+FoxP3+ cells). Nox2-deficient Tregs are 
found to have increased expression levels of CTLA-4, CD39, CD73, 
and GITR, which are all involved in suppression through different 
mechanisms (22–24). Nox2-deficient Tregs also exhibit higher 
nuclear levels of FoxP3 and the p65 subunit of NF-κB, which could 
drive the transcription of CD25. Indeed, previous studies have 
shown that FoxP3, induced by CD28 signaling in human CD4+ T 
Figure 9. Schematic of cellular and 
molecular mechanisms through 
which Nox2 in CD4+ T cells regulates 
Ang II–induced hypertension and 
heart remodeling. Deficiency of Nox2 
in Tregs results in increased numbers 
of Tregs in the heart and vessels 
and protects against the develop-
ment of hypertension, interstitial 
cardiac fibrosis, and cardiomyocyte 
hypertrophy. Mechanistically, the 
deficiency of Nox2 in Tregs enhances 
their suppressive function through an 
increase in nuclear levels of FoxP3 and 
NF-κB activation, and higher levels of 
GITR, CTLA-4, CD39, CD73, and CD25. 
The higher CD25 levels may drive an 
increased STAT5 phosphorylation 
under IL-2 stimulation, and lead to 
a positive feedback promoting sup-
pression. The deficiency of Nox2 also 
drives a change in balance between 
Tregs and Th17 cells to a more antiin-
flammatory profile, with higher IL-10 
and lower IL-17 levels.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
3 0 9 8 jci.org   Volume 128   Number 7   July 2018
(4–6, 46, 47). The involvement of Nox2-expressing T cells in Ang 
II–induced hypertension was suggested in a study in which the adop-
tive transfer of T cells into RAG-deficient mice (which lack T and B 
cells) restored hypertensive responses to Ang II, with full manifes-
tation of this requiring T cells with a functional Nox2 (13). Howev-
er, the role of different T cell subsets was not explored. Recently, it 
was reported that during Ang II–stimulated hypertension there is an 
accumulation of oxidatively modified isoketal-protein adducts in 
dendritic cells, which activate these cells and promote CD8+ T cell 
activation/proliferation and hypertension (48). Nox2 in dendritic 
cells may contribute to the formation of these oxidation products, 
and it was previously shown that dendritic cell Nox2 is involved in 
antigen presentation via MHC class II as a consequence of regulating 
phagosomal pH (49). In the current study, we identify, for the first 
time to our knowledge, a pivotal role of Nox2 in Tregs in regulating 
Ang II–induced hypertension and cardiac remodeling. Remarkably, 
Nox2 deletion solely in Tregs in adoptive transfer studies is sufficient 
to induce substantial inhibition of Ang II–induced hypertension and 
particularly interstitial cardiac fibrosis, pointing to the importance 
of Treg Nox2 in these processes. We observed increased numbers of 
Nox2-deficient Tregs in the heart, aorta, and kidney during Ang II 
infusion. It is likely that both vascular and renal Treg infiltration may 
contribute to the changes in Ang II–induced hypertension (although 
we do not find significant changes in renal function in Nox2fl/flCD-
4Cre+ mice). The changes in Ang II–induced cardiac fibrosis and 
remodeling are likely to be due in large part to the direct effects of 
Tregs in the heart rather than secondary to the change in blood pres-
sure, since cardiac fibrosis and remodeling are to a significant extent 
independent of hypertension in this model (Supplemental Figure 1).
In conclusion, this study uncovers a crucial role of Nox2 in 
CD4+CD25+FoxP3+ Tregs in regulating Ang II–induced hyperten-
sion and cardiac remodeling. The current results suggest that tar-
geting Nox2 in Tregs might be a useful strategy in cardiovascular 
diseases. Given that Treg-based cell therapy is already in early clin-
ical trials in transplant rejection (50), and that several approaches 
to Nox2 inhibition are feasible, studies to investigate the impact of 
Treg Nox2 in such pathological settings are also warranted.
Methods
Mice and in vivo studies. All studies were performed in 6- to 8-week-old 
male mice on a C57BL/6J background. Globally Nox2-deficient mice 
(Nox2–/y) were originally acquired from The Jackson Laboratory. Nox-
2fl/flCD4Cre+ mice were generated by crossing of CD4-Cre males (pro-
vided by R. Noelle, King’s College London) with Nox2fl/fl females (6). 
Gene-modified mice were compared with matched WT littermates.
Ang II (1.1 mg/kg/d) was infused via subcutaneous osmotic 
minipumps (model 1002, Alzet) implanted under 2% isoflurane anesthe-
sia. Blood pressure was determined by the tail cuff method (MK-2000ST, 
Muromachi Kikai). Echocardiography was performed in mice under 
1.5% isoflurane anesthesia using a VisualSonics Vevo 2100 imaging sys-
tem (FUJIFILM) (5). Renal function was assessed in response to an acute 
i.p. saline challenge in a metabolic cage (6). Metabolites were analyzed 
on an Advia 2400 Chemistry System (Siemens AG).
Flow cytometry. Hearts were perfused with 0.9% NaCl through 
the left ventricle before harvesting. Single-cell suspensions were pre-
pared by digestion of heart, kidney, or aorta in a mixture of collage-
nase (1 mg/ml; catalog C5238, Sigma-Aldrich), DNase (160 IU/ml), 
that STAT5 activation in Tregs correlates with FoxP3 expression 
and their proliferative capacity (41), which in Nox2-deficient Tregs 
might generate a positive feedback of suppression.
The enhanced NF-κB activation in Nox2-deficient Tregs is 
rather analogous to findings that we and others have reported in 
macrophages, where Nox2 deficiency results in hyperactivation of 
NF-κB in response to lipopolysaccharide (31, 42). We showed that 
the increased NF-κB activation is related to a Nox2-dependent 
regulation of nuclear redox state (31), and it is conceivable that a 
similar mechanism may contribute to the increase in nuclear p65 
and FoxP3 levels observed in the current study. Previous work has 
shown the importance of NF-κB in the development and suppres-
sive function of Tregs, at least in part through the regulation of tran-
scription of FoxP3 and CD25 (29, 30, 43, 44). Therefore, it is likely 
that the increased nuclear levels of FoxP3 and NF-κB in Nox2-defi-
cient Tregs contribute to their higher suppressive capacity.
Interestingly, at least part of the effect of Nox2-deficient Tregs 
is related to a greater inhibition of Th17 cells, which are found in 
reduced numbers in Nox2fl/flCD4Cre+ compared with Nox2fl/fl heart, 
vessels, and kidneys during Ang II infusion. This change in Treg/
Th17 balance is accompanied by a higher level of IL-10 and a lower 
level of IL-17 in the hearts of Nox2fl/flCD4Cre+ compared with Nox-
2fl/fl mice after Ang II infusion, indicating a switch from a pro- to an 
antiinflammatory phenotype when Nox2 is deleted in Tregs. Our in 
vitro coculture studies suggest that the reduction in IL-17 levels is 
not related to a deficiency of Nox2 in Teffs but reflects the effects 
of Nox2-deficient Tregs (Figure 5H), consistent with the idea that 
there is a regulatory interplay between Tregs and Th17 cells (19).
In addition to an increase in CD4+CD25+ Tregs (conventional 
Tregs) in heart and aorta of Nox2fl/flCD4Cre+ mice, we also observe 
an increased percentage of CD8+ Tregs in these tissues. This find-
ing is most likely related to the CD4Cre-mediated targeting of 
Nox2 during the double-positive phase of maturation of these cells 
in the thymus. Indeed, double-positive CD4+CD8+ cells in Nox2fl/
flCD4Cre+ mice are found to be Nox2-deficient. These results 
suggest that Nox2 deficiency may have similar effects in conven-
tional Tregs and CD8+ Tregs and that the latter cell type may also 
contribute to the effects observed in the current study. Neverthe-
less, the experiments with adoptive transfer of CD4+CD25+ Tregs 
clearly support the contention that Nox2 deficiency in convention-
al Tregs increases their suppressive ability and confers protection 
against Ang II–induced hypertension and cardiac fibrosis.
In the present study, we also find that the hearts of Nox2fl/
flCD4Cre+ mice express modestly higher levels of c-Met, CCR4, 
and CXCR3 mRNA than WT littermate hearts. Interestingly, 
CXCR3-positivity is reported to identify CD4+FoxP3+ Tregs with 
enhanced homing and suppressive capacity (45), while a recent 
study showed that a c-Met+CCR4+CXCR3+ phenotype is a special-
ized homing “signature” to instruct T cell cardiotropism (17). We 
speculate that these changes may contribute, at least in part, to the 
higher number of Tregs found in the hearts, aortae, and kidneys of 
Nox2fl/flCD4Cre+ compared with control mice as well as the higher 
proportion of Nox2-deficient compared with WT Tregs found in 
the hearts of WT mice after adoptive transfer.
Previous studies showed that Nox2 expressed in cardiomyo-
cytes, endothelial cells, and neurons contributes to the pathophys-
iology of Ang II–induced hypertension and cardiac remodeling 
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GAGCATTTC, reverse ACGATTGGGTTTCAGCAGAC; CXCR3: 
forward GTGGCTGCTGTGCTACTGAG, reverse AAGGCCCCTG-
CATAGAAGTT; β-actin: forward CTGTCGAGTCGCGTCCACCC, 
reverse ATGCCGGAGCCGTTGTCGAC; CD25: forward TGGTC-
TATATGCGTTGCTTGCTTAGG, reverse TTCTCGATTTGTCAT-
GGGAGT; GITR: forward ATGAGGCCTGGTCTTCCTCT, reverse 
TTGTGCTAAACGTGGTGCTC; CTLA-4: forward TGGACCCT-
GAGCATCTCTCT, reverse CAGGTGTCTGCCTAGCCTTC; CD73: 
forward GCCTATGCCTTTGGCAAATA, reverse AGGTTTCCCAT-
GTTGCATTC; CD39: forward CAAGGGCTGCGAGATAAGAC, 
reverse GCACCAGGGAACTTGGTAGA.
NF-κB activity. Jurkat cells (clone EC6-1, ATCC TIB-152) were 
stimulated with Dynabeads Human T activator CD3/CD28 (1:1) for 
12 hours. The cells were then transfected with NF-κB firefly luciferase 
(pGL4.32[luc2P/NF-κB-RE/Hygro] vector, Promega) and thymidine 
kinase Renilla luciferase constructs (phRL-TK, Promega) using elec-
troporation in T cell nucleofector media (Lonza). Plasmids expressing 
minimal promoter firefly and thymidine kinase Renilla were used as 
controls. Luciferase activities in cell lysates were determined using 
the Dual-Glo luciferase system (Promega) in a plate luminometer 
(Mithras LB 940, Berthold).
Immunofluorescence and ImageStream. Levels of nuclear p65 and 
FoxP3 were evaluated in CD4+CD25+ T cells after stimulation with anti-
CD3 (2 μg/ml) plus anti-CD28 (4 μg/ml). Cells were fixed with parafor-
maldehyde 4% and stained with anti-p65 Ab (catalog sc-372, Santa Cruz 
Biotechnology) and anti-mouse FoxP3 Ab (catalog 14-5773-82, eBiosci-
ence) and then with Alexa Fluor 488 anti-rabbit Ab and Alexa Fluor 633 
anti-rat Ab. Nuclei were stained with DAPI (Sigma-Aldrich). Cell images 
were acquired by confocal microscopy (Leica TCS SP5).
Levels of nuclear FoxP3 and p65 and colocalization of FoxP3/p65 
in CD4+ T cells purified from Nox2–/y and WT mice were also deter-
mined using imaging flow cytometry. CD4+ T cells were stimulated 
with anti-CD3 (4 μg/ml) plus anti-CD28 (4 μg/ml) for 60 minutes and 
stained with anti-CD4–PE/Cy7 (catalog 25-0041-82, eBioscience) for 
30 minutes. Cells were then fixed, permeabilized, and stained with 
anti-FoxP3–APC, rabbit anti-p65, DAPI, and goat Alexa Fluor 488 
anti-rabbit Ab. Cell images were acquired in ImageStreamX MKII 
(Merck Millipore) and analyzed using IDEAS 6.2 software (NIH). 
Nuclear translocation and colocalization wizards available in the soft-
ware guided the analyses. Parameters were evaluated in CD4+FoxP3+ 
cells (500–5,000 cells per group). The coefficient of similarity (Cs) 
was defined as “Similarity” or “Bright field similarity” in channels 
corresponding to FoxP3, DAPI, and p65.
Cytokine production and immunoblotting. Levels of TNF-α and 
IFN-γ were determined in supernatants of cocultures of Teffs and 
Tregs using a Cytometric Bead Array kit (BD Pharmingen). Levels of 
IL-17 and IL-10 were determined by ELISA using kits from R&D Sys-
tems and eBioscience, respectively.
Nuclear protein from purified Tregs was immunoblotted for FoxP3 
(catalog 145773-82, eBioscience) and histone H3 (catalog 4499S, Cell 
Signaling Technology) using standard methods. Anti-rabbit 680VW 
and anti-rat 800VW Licor Abs (catalog 925-68071 and 925-32219, 
respectively) were used as secondary Abs. Signals were analyzed using 
the Odyssey CLx infrared Imaging System.
Histology. Leukocyte infiltration, cardiomyocyte hypertrophy, and 
fibrosis were analyzed in paraffin-embedded sections stained with 
H&E, wheat germ agglutinin, and Picrosirius red, respectively. Cryo-
and hyaluronidase (500 IU/ml) at 37°C for 30 minutes. Samples were 
triturated and sequentially filtered through a 40-μm nylon mesh. Red 
blood cells were lysed in 2% NH4Cl buffer. Nonspecific interactions 
were blocked with anti–mouse CD16/CD32 Ab (10 μg/ml, 1:50; cat-
alog 14-0161-82, eBioscience) before staining. Anti-CD8–APC-Cy7, 
anti-CD45–FITC, anti-TCRβ–PE-Cy7, anti–MHC II–PerCP, anti-
RORγT–BV421, anti-Nox2, anti-CD25–PE, anti–phospho-STAT5 Abs 
and anti-CD4 PercP were purchased from BD Pharmingen (catalog 
561967, 553080, 560729, 562363, 562894, 611414, 553075, 562077, 
and 553052 respectively). Anti-CD4–eFluor450 and anti-FoxP3–
APC Abs were acquired from eBioscience (catalog 48-0041-80 and 
17-5773-82, respectively). Anti–rat Alexa Fluor 633 and anti–rabbit 
Alexa Fluor 488 were acquired from Invitrogen (catalog A21094 and 
A3273, respectively). The FoxP3 Transcription Factor Staining Buffer 
Set kit was from eBioscience (catalog 00-5523-00).
In order to determine the protein levels of CTLA-4, CD39, CD73, 
and GITR, Tregs were purified from lymph nodes and spleens using 
a Dynabeads FlowComp Mouse CD4+CD25+ Treg kit (Invitrogen). 
The mean fluorescence intensity corresponding to fluorochromes 
associated with CTLA-4, CD39, CD73, and GITR was evaluated in 
CD25+FoxP3+ cells. For this assay, anti-FoxP3–PE/Cy7 from Thermo 
Fisher Scientific (catalog 25-5773-82) and anti-CD25–PerCP-Cy5.5, 
anti–CTLA-4–APC, anti-GITR–FITC, anti-CD39–PE, and anti-CD73–
Brilliant Violet 421 from Biolegend (catalog 102029, 106309, 126308, 
143803, and 127217, respectively) were used.
Levels of phospho-STAT5 were evaluated in CD4+ T cells purified 
(>90%) from lymph nodes and spleens (Dynabeads Untouched Mouse 
CD4 Cells kit, catalog 11415D, Invitrogen). After stimulation with IL-2 
(100 IU/ml), cells were fixed in 4% paraformaldehyde, stained with 
anti-CD4–eFluor450 and anti-CD25 PE-Cy7 Ab, incubated 30 min-
utes in permeabilization buffer (0.5% BSA, 0.5% saponin in PBS), and 
stained with FoxP3-APC and anti–phosho-STAT5–PE.
Samples were acquired in an LSRFortessa flow cytometer (BD 
Biosciences) and analyzed using FlowJo software 9.7.5.
Adoptive transfer of purified Tregs. Tregs were purified (>90%) 
from lymph nodes and spleens using a Dynabeads FlowComp Mouse 
CD4+CD25+ Treg kit. Immediately after purification, 1 × 106 cells were 
injected in the tail vein, and the minipump containing Ang II was 
implanted afterward.
Superoxide production. Superoxide production was determined by 
flow cytometry using 10 μM dihydroethidium (6) in CD4+ T cells purified 
from Nox2fl/flCD4Cre+ and Nox2fl/fl mice and stimulated with anti-CD3 
(2 μg/ml) plus anti-CD28 (4 μg/ml). Some cells were incubated with 
diphenyleneiodonium (1 μM) before TCR stimuli (negative controls).
In vitro suppression assay. Teffs (CD4+CD25–) and Tregs (CD4+CD25+) 
were purified from spleen and lymph nodes. APCs were obtained by incu-
bation of total splenocytes with anti-CD4 and anti-CD8 Abs, followed 
by negative selection using Dynabeads from the Dynabeads Untouched 
Mouse CD4 Cells kit. Teffs were stained with CFSE (51) and incubated 
with Tregs under stimulation by anti-CD3ε (4 μg/ml) and APCs (1:2).
Quantitative PCR. RNA was extracted using RNeasy Mini Kits 
(Qiagen). After cDNA generation, SYBR Green real-time PCR 
was performed using the ΔΔCt method and β-actin for normaliza-
tion. Primers were as follows: Nox2: forward ACTCCTTGGGT-
CAGCACTGG, reverse GTTCCTGTCCAGTTGTCTTCG; CCR4: 
forward ATCCTGAAGGACTTCAAGCTCCA, reverse AGGTCT-
GTGCAAGATCGTTTCATGG; c-Met: forward TCCTGCACTGT-
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